Jefferies Global Healthcare Conference
Logotype for Sandoz Group AG

Sandoz (SDZ) Jefferies Global Healthcare Conference summary

Event summary combining transcript, slides, and related documents.

Logotype for Sandoz Group AG

Jefferies Global Healthcare Conference summary

18 Nov, 2026

Biosimilar opportunity and growth outlook

  • 13 biosimilars launched in the past 20 years; plan to launch 40–50 over the next 15 years, supported by vertically integrated capabilities.

  • Nearly $400 billion of biologic sales face loss of exclusivity over the next 10+ years; global biosimilar share is ~20%, with an aspiration to exceed 30%–35% within 10 years.

  • Management sees competitor numbers per biologic asset declining; entry requires years of development, $100 million, capacity, IP and global commercial reach.

  • 2027 launches include insulins and other European products, four biosimilars in Japan, and U.S. aflibercept in H2; Brazil’s government partnership supports a PDP program.

  • Enbrel is planned for U.S. launch in 2029; pembrolizumab and other assets are expected to support growth into the 2029–30s. Biosimilar business grew 17% last quarter.

Manufacturing and profitability

  • Slovenia’s completed large fed-batch facility has 120,000 liters of capacity and is moving through regulatory phases; capacity can be expanded, with more volume shifting to the internal network from 2029.

  • Target at least 60% of volume from the vertically integrated network by 2035; small fed-batch, large fed-batch and continuous manufacturing enable supply flexibility across yields.

  • Partner products are less profitable than fully integrated products but generally more profitable than simple small molecules; internal capacity can reduce costs and relieve supply bottlenecks, including for erythropoietin.

  • Plans include holding SG&A flat while pursuing procurement and operating efficiencies; EBITDA delivery is expected to improve ~1 percentage point annually toward ~30% by 2035.

  • In-house candidates are planned to rise from two to seven; facilities are in place, while most resulting assets are expected to launch from the mid-2030s.

Market dynamics and strategic focus

  • German open-house tenders drove biosimilar volume and penetration, with tender pricing determined by competition; volume exceeded forecasts, while sufficient supply is secured for the 2027 financial plan.

  • Aflibercept own-label opportunity has committed volumes, with value expected from H2 2027 and carryover into 2028; own-label use is described as product-by-product flexibility, not a strategic shift.

  • GLP-1 launches have begun in Brazil, with a second brand planned following semaglutide INN approval; Canada launch is planned later this year. Early markets remain supply-constrained and demand is expected to exceed supply.

  • GLP-1 sales are expected to reach billions of dollars, but the value is too early to quantify; the longer-term target to more than double sales value by 2035 excludes GLP-1s.

  • Value-added medicines are not a focus; management prioritizes biosimilars and generics amid the coming patent-loss opportunity. Transformational M&A is viewed as potentially distracting, with M&A not a priority for the first four to five years after the spin.

  • Penicillin B2B performance was hurt by Chinese dumping through Indian manufacturers; management expects the impact to wash out by year-end, while retail is described as stable.

Partial view of Summaries dataset, powered by Quartr API
AI can get things wrong. Verify important information.
All investor relations material. One API.
Learn more

Latest events from Sandoz